Okuma T, Yamashita I, Takahashi R, Itoh H, Kurihara M, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K
National Center Hospital for Mental, Nervous, and Muscular Disorders, Tokyo, Japan.
Pharmacopsychiatry. 1989 Mar;22(2):47-53. doi: 10.1055/s-2007-1014577.
The therapeutic effects of carbamazepine (CBZ) were evaluated in 103 patients with affective disorders, 54 with schizophrenic disorders, and 26 with schizoaffective disorders by a multi-institutional open study. The rate of marked and moderate improvement was 72.8% in affective disorders, 54.6% in schizophrenic disorders, and 61.5% in schizoaffective disorders. Symptom items of the Clinical Psychopharmacology Research Group rating scale for mania showed significant improvement in the patients with affective disorders as well as in those of the other two groups. In the Brief Psychiatric Rating Scale as applied to patients with schizophrenic or schizoaffective disorders, symptom items related to affect and emotion showed significant improvement. The antimanic efficacy of CBZ was also noted in many poor responders to lithium. Side-effects were observed in 82 patients (44.8%), and abnormal laboratory findings in 37 patients (44.8%), and abnormal laboratory findings in 37 patients. The present study seems to confirm the usefulness of CBZ for the treatment of affective disorders and in some cases, of schizophrenic and schizoaffective disorders.
通过一项多机构开放性研究，对103例情感障碍患者、54例精神分裂症患者和26例分裂情感性障碍患者评估了卡马西平（CBZ）的治疗效果。情感障碍患者中显著和中度改善率为72.8%，精神分裂症患者为54.6%，分裂情感性障碍患者为61.5%。临床精神药理学研究组躁狂评定量表的症状项目在情感障碍患者以及其他两组患者中均显示出显著改善。在应用于精神分裂症或分裂情感性障碍患者的简明精神病评定量表中，与情感和情绪相关的症状项目显示出显著改善。在许多对锂盐反应不佳的患者中也观察到了CBZ的抗躁狂疗效。82例患者（44.8%）出现副作用，37例患者（44.8%）出现实验室检查异常。本研究似乎证实了CBZ对情感障碍以及某些情况下对精神分裂症和分裂情感性障碍治疗的有效性。
